Drug Trial Radar · NCT07828522
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Oct 9, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-center, single-arm, exploratory pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of F182112 in combination with isatuximab and lenalidomide in transplant-eligible patients with newly diagnosed multiple myeloma. The study will also explore preliminary proof-of-concept signals of deep responses and minimal residual disease (MRD) negativity with this regimen, thereby informing the design of a subsequent phase II clinical trial.
Conditions
- Multiple Myeloma (MM)
- Transplant-eligible Patients
Interventions
F182112 Plus Isatuximab and LenalidomideDrug
Induction treatment phase: F182112: Administered by intravenous infusion. Patients will receive three step-up doses of F182112 at 3 μg/kg, 30 μg/kg, and 180 μg/kg on Days 1, 4, and 8 of Cycle 1, respectively, followed by intravenous administration of F182112 at 180 μg/kg once weekly. Isatuximab: Administered by intravenous infusion at 10 mg/kg. Patients will receive isatuximab on Days 1, 8, 15, and 22 of Cycle 1, and on Days 1 and 15 of each cycle from Cycle 2 to Cycle 6. Lenalidomide: Administered orally at 25 mg on Days 1-21 of each cycle. Maintenance treatment phase: F182112: Administered by intravenous infusion at 180 μg/kg once every 2 weeks. If sustained MRD negativity is maintained for more than 6 months after completion of induction treatment, the investigator may consider adjusting the subsequent dosing frequency to once every 4 weeks. Isatuximab: Administered by intravenous infusion at 10 mg/kg. During the maintenance treatment phase, isatuximab will be administered once
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and outcomes of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) occurring from the initiation of the first study treatment through the end of Cycle 6, or through 30 days after premature discontinuation of study tTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.